Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Dec 6, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving the way Black or African American men with metastatic prostate cancer receive counseling about tumor genetic testing. The goal is to ensure that these patients have fair access to information and support as they consider genetic testing, which can help guide their treatment options. The study is currently recruiting participants who are 18 years or older, identify as Black or African American, and have been diagnosed with metastatic prostate cancer.

Eligible participants will be asked to understand and comply with the study procedures and will need to be fluent in English. They can expect to discuss their options for tumor genetic testing, which may involve testing tissue samples or blood to find out more about their cancer. This trial aims to create a helpful tool for patients to better understand their genetic testing options and make informed decisions about their care. If you or someone you know fits these criteria and is interested, this could be an important opportunity to participate in research that supports a more equitable healthcare experience.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• Stage 1:
• • 1. Age 18-years-old or older
• • 2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.
• • 3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
• • 4. Able to understand study procedures and to comply with them for the entire length of the study.
• • 5. Able to understand a written information sheet and willing to verbally consent.
• • 6. Fluent in English (reading, writing, and speaking)
• Stage 2:
• • 1. Age 18-years-old or older
• • 2. Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.
• • 3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
• • 4. Able to understand study procedures and to comply with them for the entire length of the study.
• • 5. Fluent in English (reading, writing, and speaking).
• 6. Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:
• • 1. Somatic DNA testing of already-collected tissue.
• • 2. Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
• • 3. Blood-based DNA testing to evaluate for circulating tumor DNA.
• • 7. Able to understand a written informed consent document and willing to sign it.
• Exclusion Criteria:
• • Contraindication to any study-related procedure or assessment in either stage.